Silexion Therapeutics (NASDAQ:SLXN) Shares Down 7.1% – Here’s What Happened

Silexion Therapeutics Corp (NASDAQ:SLXN) shares traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $2.10 and last traded at $2.10. 90,136 shares were traded during mid-day trading, a decline of 15% from the average session volume of 105,631 shares. The stock had previously closed at $2.26.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on shares of Silexion Therapeutics in a report on Friday, November 1st. They issued a “buy” rating and a $9.00 price objective for the company.

Silexion Therapeutics Price Performance

The stock has a 50-day moving average of $2.52.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Wildcat Capital Management LLC purchased a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics comprises 0.3% of Wildcat Capital Management LLC’s portfolio, making the stock its 7th biggest position. Wildcat Capital Management LLC owned about 7.38% of Silexion Therapeutics at the end of the most recent reporting period. 10.95% of the stock is owned by institutional investors.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.